Literature DB >> 21881047

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.

Ayalew Tefferi1, Thitina Jimma, Naseema Gangat, Rakhee Vaidya, Kebede H Begna, Curtis A Hanson, Daniel L Van Dyke, Domenica Caramazza, Animesh Pardanani.   

Abstract

DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 parameters that can reliably predict death in the first 2 years of disease. After a median of 8.2 years from time of referral to the Mayo Clinic, 564 deaths (64% of patients in the study) had been recorded. Risk factors associated with > 80% 2-year mortality included monosomal karyotype, inv(3)/i(17q) abnormalities, or any 2 of the following: circulating blasts > 9%, leukocytes ≥ 40 × 10(9)/L, or other unfavorable karyotype. Patients with any 1 of these risk profiles (n = 52) displayed significantly shorter overall survival than those otherwise belonging to a high-risk category per DIPSS-plus (n = 298); respective median survivals were 9 and 23 months (hazard ratio 2.2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches.

Entities:  

Mesh:

Year:  2011        PMID: 21881047     DOI: 10.1182/blood-2011-08-371096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

2.  Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.

Authors:  Katsuto Takenaka; Kazuya Shimoda; Naoyuki Uchida; Taizo Shimomura; Koji Nagafuji; Tadakazu Kondo; Hirohiko Shibayama; Takehiko Mori; Kensuke Usuki; Taichi Azuma; Yutaka Tsutsumi; Junji Tanaka; Hitomi Dairaku; Keitaro Matsuo; Keiya Ozawa; Mineo Kurokawa; Shunya Arai; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-10-19       Impact factor: 2.490

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

4.  One thousand patients with primary myelofibrosis: the mayo clinic experience.

Authors:  Ayalew Tefferi; Terra L Lasho; Thitina Jimma; Christy M Finke; Naseema Gangat; Rakhee Vaidya; Kebede H Begna; Aref Al-Kali; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 5.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

6.  Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.

Authors:  Omar Abdel-Wahab; Animesh Pardanani; Olivier A Bernard; Guido Finazzi; John D Crispino; Heinz Gisslinger; Robert Kralovics; Olatoyosi Odenike; Kapil Bhalla; Vikas Gupta; Giovanni Barosi; Jason Gotlib; Paola Guglielmelli; Jean-Jacques Kiladjian; Pierre Noel; Mario Cazzola; Alessandro M Vannucchi; Ronald Hoffman; Tiziano Barbui; Juergen Thiele; Richard A Van Etten; Tariq Mughal; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-03-28       Impact factor: 10.047

Review 7.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

8.  Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Authors:  Mohamad Bassam Sonbol; Belal Firwana; Ahmad Zarzour; Mohammad Morad; Vishal Rana; Ramon V Tiu
Journal:  Ther Adv Hematol       Date:  2013-02

9.  Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Sherry Pierce; Jorge Cortes; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-02-04

10.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Authors:  A Tefferi; P Guglielmelli; T L Lasho; G Rotunno; C Finke; C Mannarelli; A A Belachew; A Pancrazzi; E A Wassie; R P Ketterling; C A Hanson; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.